Literature DB >> 28760300

First-line Therapeutic Strategies for Myelodysplastic Syndromes.

Valeria Santini1.   

Abstract

The precise diagnostic tests and subsequent prognostic stratification for patients with myelodysplastic syndrome (MDS) are often cumbersome, yet they are the basis of successful therapy. Diverse treatment options are available for these patients; however, the decisions in real-life are often not grounded on the available evidence. Although the International Prognostic Scoring System and revised International Prognostic Scoring System are still driving the medical approach to MDS patients, additional variables must be considered when therapeutic intervention is needed. A rational scheme for first-line therapy is described that allows for the possibility of selecting the optimal individual therapy for MDS patients.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Erythropoietic stimulating agents; First-line therapy; Hypomethylating agents; Myelodysplastic syndromes; Somatic mutations

Mesh:

Substances:

Year:  2017        PMID: 28760300     DOI: 10.1016/j.clml.2017.02.013

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  2 in total

1.  The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes.

Authors:  Roberto Castelli; Riccardo Schiavon; Giorgio Lambertenghi Deliliers
Journal:  Med Oncol       Date:  2018-02-08       Impact factor: 3.064

2.  Targeting miR-126 disrupts maintenance of myelodysplastic syndrome stem and progenitor cells.

Authors:  Huafeng Wang; Jie Sun; Bin Zhang; Dandan Zhao; Hongyan Tong; Herman Wu; Xia Li; Yingwan Luo; Dan Dong; Yiyi Yao; Tinisha McDonald; Anthony S Stein; Monzr M Al Malki; Flavia Pichiorri; Nadia Carlesso; Ya-Huei Kuo; Guido Marcucci; Ling Li; Jie Jin
Journal:  Clin Transl Med       Date:  2021-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.